Added to YB: 2025-11-11
Pitch date: 2025-11-07
NVO [bearish]
Novo Nordisk A/S
-5.91%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 298.75
Price Target
N/A
Dividend
3.63%
EV/EBITDA
8.96
P/E
13.76
EV/Sales
4.74
Sector
Pharmaceuticals
Category
N/A
Stocks Update 7/11/2025 - Novo Nordisk (NVO)
NVO (earnings): Q3 results disappointing with revenue/EBIT below expectations amid $9B restructuring. Ozempic/Wegovy growth slowing due to pricing pressure & US reimbursement concerns. Insulin franchise contracting. Guidance downgraded to single-digit growth 2025. Strong pipeline intact but margin expansion era ending.
Read full article (2 min)